Loading…
← CockpitCompetitor Analysis › AMBU-B.CO Ambu A/S Class BOpen in the cockpit ↗

Ambu A/S Class BAMBU-B.COCompetitor analysis, valuation and peers

Denmark · DKK·Health Care›Medical Specialties

Makes single-use medical devices, including disposable endoscopes, resuscitators and diagnostic equipment.

Momentum leader 83
Mkt cap
$3.47B
US dollars, full cap
Free float
77%
of shares outstanding
$/day
$10.6M
20-day average traded
Fwd P/E
28.8×
forward earnings
ROIC−WACC
+4.3 pp
WACC 6.2%
Hurdle
-0 pp
Req g minus delivered
Next earnings
71 days
28 Jan 2027
Close · DKKDKK 89.20
1D-0.2%
1W+2.4%
1M+16.0%
3M+16.1%
6M+30.9%
YTD+1.4%
1Y+3.9%
ATR %2.7%
52w lowhigh4.3% off high

What Ambu A/S does

Makes single-use medical devices, including disposable endoscopes, resuscitators and diagnostic equipment.

Sells disposable devices used once, so hospitals reorder steadily. In endoscopy it sells reusable monitors as equipment and the disposable scopes as the recurring item. Resuscitators are an older, steadier product line.

Products and services

  • Single-use endoscopes (aScope)
  • Resuscitators (Ambu bag)
  • Anaesthesia/patient monitoring devices

Customers

  • Hospitals and healthcare providers globally

Where it sits in the supply chain

  • Medical devices
  • Single-use medical devices
  • Endoscopy + emergency/diagnostic…

What could go right

  • Hospital shift from reusable to single-use devices (infection control)
  • New product category expansion

What could go wrong

  • Hospital capital budget/reimbursement pressure
  • Competitive entry from larger med-tech players

Moat: narrow (IP / patents, switching costs). Pioneer in single-use endoscopy, reducing cross-infection risk and hospital reprocessing costs.

Headquarters: Ballerup, Denmark · Founded: 1937 · Employees: 5,877

Named competitors

Ambu A/S at a glance

Size Ambu A/S (AMBU-B.CO) is a Denmark Health Care company (Medical Specialties) with a market value of $3.47B, the 25th largest of 60 Denmark companies the cockpit tracks. Shares closed at DKK 89.20 on 18 Nov 2026.

Performance Over six months the shares gained 30.9%, against -0.4% for the median peer and +6.3% for the Denmark market (cap-weighted) — 7th highest of 21 in its peer set.

Growth Revenue grew 7.2% over the last twelve months (peer median +6.0%); the operating margin is 13.2% (peer median 11.6%).

Valuation It trades at 28.8× forward earnings against a peer median of 23.7× (7th most expensive of 19).

Price implies For today's price to make sense, revenue must grow about 10% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is -0 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 4.3 points above its cost of capital (6.2% WACC).

Next results Next results expected around 28 Jan 2027 (exchange calendar; dates can move).

Relative performance

10012014021 May 202621 Aug 202618 Nov 2026AMBU-B.CO 134Peer median 101
Six months, rebased to 100: Ambu A/S against the median of its 20 peers (local-currency closes).

Ambu A/S financials

Reported figures in DKK; fiscal year ends 2026-09-30. TTM = trailing twelve months.
TTMFY2026FY2025FY2024FY2023
RevenueDKK 6.47BDKK 6.47BDKK 6.04BDKK 5.39BDKK 4.78B
Revenue growth—+7%+12%+13%—
Gross profitDKK 3.89BDKK 3.58BDKK 3.38BDKK 2.96BDKK 2.49B
EBITDADKK 1.26BDKK 1.26BDKK 1.16BDKK 1.01BDKK 632M
Net incomeDKK 642MDKK 642MDKK 609MDKK 235MDKK 168M
Free cash flowDKK 861MDKK 861MDKK 674MDKK 725MDKK 447M
Capital expenditureDKK 578MDKK 578MDKK 384MDKK 289MDKK 326M
Total debtDKK 593MDKK 593MDKK 547MDKK 558MDKK 584M

Quarterly statements and history in the cockpit →

Ambu A/S competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-25%0%+25%+50%+75%-20%0%+20%4203AXGNPLSE603658TECNTMDX6030146883016033011SXP300003IRTCNVSTAFX002432CDNAFIE688114002223STVNAMBU-B.CO6-month return →1-month return →
Up and to the right = strong over both horizons. Ambu A/S is the large dot.

Fundamentals: revenue growth against valuation

-25%0%+25%+50%25×50×75×100×4203AXGN603658TECNTMDX603014688301603301300003IRTCNVST002432CDNASTVNAMBU-B.CORevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Ambu A/S is the large dot.

Capital: growth delivered against growth the price implies

0%+25%+50%+75%0%50%4203AXGN603658TECNTMDX6030146033011SXP300003IRTC002432FIE688114STVNAMBU-B.COGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Ambu A/S is the large dot.

Ambu A/S competitors and peer comparison

Head to head with its named competitors (AMBU-B.CO vs BSX vs 7733.T vs MDT)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Ambu A/S AMBU-B.CO$3.47B+31%+7%13%28.8×10.0%
Boston Scientific BSX$63.3B-23%+9%21%14.1×5.8%
Olympus 7733.T$12.7B+5%+9%18%18.7×-6.5%
Medtronic MDT$129B+30%+10%20%16.8×9.1%

How Ambu A/S compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Ambu A/S against its 20 peers (data as of 18 Nov 2026)
MeasureAMBU-B.COPeer medianRank in peer set
1-month return+16.0%+3.0%4th highest of 21
6-month return+30.9%-0.4%7th highest of 21
Distance from 52-week high-4.3%-27.7%2nd highest of 21
Revenue growth (TTM)+7.2%+6.0%11th highest of 21
Operating margin13.2%11.6%6th highest of 20
Forward P/E28.8×23.7×7th most expensive of 19
Growth the price implies (Req g, 7 yrs)10.0%12.5%9th least demanding of 18
Growth delivered (Del g)+10.0%+8.1%8th highest of 18
Hurdle (Req g minus delivered)-0.0 pp+1.5 pp7th least demanding of 18
ROIC minus cost of capital+4.3 pp-1.1 pp3rd highest of 19
EV / EBITDA18.8×12.5×4th most expensive of 10
Net debt / EBITDA0.1×1.0×5th least indebted of 11

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Ambu A/S AMBU-B.CODenmark$3.47B+31%+7%13%28.8×10.0%+10.0%
Sumitomo Bakelite 4203.TJapan$3.50B+7%+15%13%15.9×8.6%+8.9%
Axogen AXGNUnited States$3.40B+33%+24%-5%87.3×52.6%+14.9%
Pulse Biosciences PLSEUnited States$3.37B+76%+1,637%-5,821%n/an/an/a
Autobio Diagnostics 603658.SSChina$3.36B+16%+3%25%20.3×-0.4%+7.2%
Tecan TECN.SWSwitzerland$3.60B+59%-4%1%35.5×45.4%+3.8%
TransMedics TMDXUnited States$3.35B+42%+28%12%43.4×38.4%+88.2%
Shandong Weigao Blood Purification Products 603014.SSChina$3.63B-1%+4%n/a20.4×-1.2%+8.1%
iRay Technology 688301.SSChina$3.31B-30%+58%24%25.7×n/an/a
Zhende Medical 603301.SSChina$3.26B-10%+8%7%42.5×22.9%-16.1%
SCHOTT Pharma AG & Co. KGaA 1SXP.DEGermany$3.73B+32%+4%15%23.0×12.7%+11.0%
Lepu Medical Technology (Beijing) 300003.SZChina$3.20B-13%-1%13%24.4×8.7%-4.2%
iRhythm IRTCUnited States$3.19B-19%+22%5%99.8×46.9%+23.0%
Envista NVSTUnited States$3.81B0%+10%12%14.7×4.8%+7.1%
Carl Zeiss Meditec AFX.DEGermany$3.17B+22%0%8%24.4×12.5%+10.8%
Andon Health 002432.SZChina$3.86B-24%-30%-26%16.1×-6.6%-7.4%
CareDx CDNAUnited States$3.91B+252%+39%1%50.6×n/an/a
Fielmann FIE.DEGermany$3.92B-3%+3%14%17.1×-5.5%+11.3%
MGI Tech 688114.SSChina$3.06B-4%+2%-7%n/a43.7%-0.1%
Jiangsu Yuyue Medical Equipment & Supply 002223.SZChina$4.18B-3%-1%13%20.0×4.9%+3.4%
Stevanato STVNUnited States$4.19B-13%+12%18%22.5×13.1%+12.1%

Questions

Who are Ambu A/S's main competitors?
Named competitors: Boston Scientific (BSX), Olympus (7733.T), Medtronic (MDT). The cockpit's measured peer set (industry) also includes Sumitomo Bakelite (4203.T), Axogen (AXGN), Pulse Biosciences (PLSE), Autobio Diagnostics (603658.SS), Tecan (TECN.SW), TransMedics (TMDX).
Is Ambu A/S expensive compared with its peers?
On forward p/e it trades at 28.8× against a peer median of 23.7×, 7th most expensive of 19 in its peer set. For today's price to make sense, revenue must grow about 10% a year for seven years (Req g). Recent delivered growth is +10%, so the hurdle is -0 pp: the price already allows for a slowdown.
How has Ambu A/S stock performed?
Over six months to 18 Nov 2026 the shares returned +30.9% against -0.4% for the median peer; over one year +3.9%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.